Avian Influenza

iGrow News Avian Influenza
Bioxytran has developed a water-soluble galectin antagonist, which is in preclinical trials as a potential treatment for Highly Pathogenic Avian Influenza (HPAI), or Bird Flu.

Bioxytran Unveils Potential Breakthrough Treatment for Bird Flu in Egg-Laying Chickens

Bioxytran has developed a water-soluble galectin antagonist, which is in preclinical trials as a potential treatment for Highly Pathogenic Avian Influenza (HPAI), or Bird Flu.

Read More
Current H5N1 surveillance efforts in the U.S. face delays due to laboratory-based testing, limiting timely containment efforts.

The Urgent Need for Better H5N1 Surveillance and Testing Infrastructure in the U.S.

Current H5N1 surveillance efforts in the U.S. face delays due to laboratory-based testing, limiting timely containment efforts.

Read More
The USDA CVB granted Zoetis a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, for use in chickens.

Zoetis Receives USDA Conditional License for Avian Influenza Vaccine

The USDA CVB granted Zoetis a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, for use in chickens.

Read More